Pharma-Bio Serv, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024
March 18, 2024 at 05:05 pm EDT
Share
Pharma-Bio Serv, Inc. reported earnings results for the first quarter ended January 31, 2024. For the first quarter, the company reported sales was USD 2.38 million compared to USD 4.24 million a year ago. Net loss was USD 0.270719 million compared to net income of USD 0.426432 million a year ago.
Basic loss per share from continuing operations was USD 0.012 compared to basic earnings per share from continuing operations of USD 0.019 a year ago. Diluted loss per share from continuing operations was USD 0.012 compared to diluted earnings per share from continuing operations of USD 0.019 a year ago.
Pharma-Bio Serv, Inc. is a compliance and technology transfer services consulting company. The Company operates through four segments: Puerto Rico technical compliance consulting, United States technical compliance consulting, Europe technical compliance consulting, and Puerto Rico microbiological and chemical laboratory testing division (Lab). The Company provides a range of compliance-related consulting services. The Company provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. The Company's technical consulting services include regulatory compliance, validation, technology transfer, engineering, project management and process support. The Company markets its services to pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies in Puerto Rico, the United States, Europe and Brazil.
PHARMA-BIO SERV, INC. 
